03.24.26 -- From Biology Grad To Manufacturing Guru

These real-world case studies highlight best practices and strategies to optimize bioconjugate drug product tech transfers and supplies in the clinical or commercial phase.

Dive into the scope of <382> for pharmaceutical closures and the regulatory landscape, which includes new required tests, instrumentation for compliance, and recommendations on implementation.

Scale-out biomanufacturing enhances flexibility, speeds timelines, lowers risk, and enables efficient parallel production for scalable, resilient biologics and advanced therapies.

Transforming the pharma workforce requires strategic partnerships and a shift toward behavioral and operational readiness, moving beyond simple technical training to ensure performance and compliance.

We discuss the trends in new molecular formats, which is one of the current drivers of renewed interest in fermentation technologies, along with some of their challenges. 

Analytical technologies like Droplet Digital PCR (ddPCR) provide a more rapid and robust approach to nucleic acid quantification for better sensitivity, accuracy, and precision in therapeutic development.

Rapid, low‑cost checks can catch construct issues that limit vector manufacturing, enabling early fixes to improve titers, avoid delays, and accelerate gene therapy programs.

Discover a disposable pen for Liraglutide 3.0 mg that demonstrates comparable usability to the reference device, helping de-risk ANDA submissions through proactive human factors evaluation.

Uncover how data-driven process design and effective technology transfer can accelerate validation readiness and help move biologics from development to commercial success faster.

Gain expert insights on mitigating risks in global pharmaceutical manufacturing by learning from Joon Chang and Tracey Partington’s decades of industry experience.

Examine how innovative technology can revolutionize your recombinant protein manufacturing processes and enhance efficiency.